SCHEMBL961310

SCHEMBL961310

Cc1c(CCl)cccc1[N+](=O)[O-]

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.67
ALDH1A1 P00352 3/20 0.67
TDP1 Q9NUW8 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.58
HSD17B10 Q99714 1/20 0.47
GPR35 Q9HC97 1/20 0.44
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 2/20 0.44
MAPK1 P28482 1/20 0.44
HPGD P15428 1/20 0.43
PKM P14618 1/20 0.42
POLB P06746 1/20 0.42
DHODH Q02127 1/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849609 0.86 TDP1 (0.60) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL14641737 0.85 TDP1 (0.69) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL27645574 0.84 ALDH1A1 (0.70) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL10902775 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL715298 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL14363082 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL16803358 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL3841885 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL1067609 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10
SCHEMBL6205360 0.81 TDP1 (0.64) TSHRALDH1A1TDP1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307540-B Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-10-15 CN claimed
EP-4400166-A2 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2024-07-17 EP claimed
CN-118307540-A Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-07-09 CN claimed
EP-3565484-B1 COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS CONTRALINE INC (US) 2024-04-03 EP claimed
US-20220031607-A1 INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR CRYSTALGENOMICS, INC. (KR) 2022-02-03 US claimed
US-20220016098-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2022-01-20 US claimed
EP-3915538-A1 INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR Crystalgenomics, Inc. (KR) 2021-12-01 EP claimed
CN-113613627-A Injection composition containing Fab I inhibitor and preparation method thereof 晶体基因技术株式会社 2021-11-05 CN claimed
EP-3824888-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2021-05-26 EP claimed
CN-112423751-A Orally administered pharmaceutical compositions comprising Fab I inhibitors and methods of making the same 晶体基因技术株式会社 2021-02-26 CN claimed
WO-2020017756-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME 크리스탈지노믹스(주) 2020-01-23 WO claimed
EP-3565484-A1 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2019-11-13 EP claimed
WO-2018129369-A1 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2018-07-12 WO claimed
US-20180185096-A1 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. 2018-07-05 US claimed
US-12383421-B2 Contraceptive devices Contraline, Inc. (US) 2025-08-12 US disclosed
CN-118307540-B Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-10-15 CN disclosed
EP-4400166-A2 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2024-07-17 EP disclosed
US-4165316-A Process for preparing sulfinyl chlorides from penicillin sulfoxides ELI LILLY AND COMPANY (US) 1979-08-21 US disclosed
EP-0000718-A2 Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-02-21 EP disclosed
US-4075203-A Process for preparing a 3-exomethylenecepham sulfoxide from penicillin sulfoxides ELI LILLY AND COMPANY (US) 1978-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016098-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME FCGRT, PEF1, SI TSHR 4334/4885ALDH1A1 4212/4885TDP1 3737/4885
US-20220031607-A1 INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR FAR1, NOTUM, IDE TSHR 4448/4885ALDH1A1 3888/4885TDP1 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.